Latest Breaking News On - Fujifilm toyama chemical - Page 2 : comparemela.com

As It Happens: Updates on COVID-19 pandemic

Follow this page for updates on a mysterious pneumonia outbreak that has struck dozens of people in China.

United statesMisamis orientalCzech republicSan diegoSan franciscoNorth islandNew zealand generalNew zealandT ai peiIloilo cityUnited arab emiratesSouth africaBruxelles capitaleSoult ukpyolsiSouth koreaSouth beach

Appili concludes enrolment in sub-study of Covid-19 antiviral treatment

Appili concludes enrolment in sub-study of Covid-19 antiviral treatment
clinicaltrialsarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from clinicaltrialsarena.com Daily Mail and Mail on Sunday newspapers.

Yoav golanAvigan reeqonuAvigan reeqonusAppili therapeuticsFujifilm toyama chemicalபுஜிஃபில்ம் டோயாமா இரசாயன

Global Response Aid Reports Midyear Sales Results for COVID Drug

/PRNewswire/ Healthcare solutions provider Global Response Aid (GRA) today reported seven-month global sales figures for its anti-viral tablet.

United arab emiratesUnited statesMitch wilsonFujifilm toyamaMary obrienHoldings corporationServices active ingredientsReddy laboratories ltdGlobal response aidFujifilm toyama chemicalActive ingredientsGlobal genericsProprietary productsஒன்றுபட்டது அரபு அமீரகங்கள்ஒன்றுபட்டது மாநிலங்களில்மிட்ச் வில்சன்

Anti-Viral backed by GRA on track to deliver Covid-19 home treatment

Anti-Viral backed by GRA on track to deliver Covid-19 home treatment DUBAI, 1 hours, 53 minutes ago Healthcare solutions provider Global Response Aid (GRA) announced that a Phase 3 US-Canada clinical trial of anti-viral Avigan (Reeqonus) will continue amid signs the drug could be effective in the treatment of patients with mild to moderate cases of Covid-19. An independent Data and Safety Monitoring Board (DSMB) recognised by the US Food and Drug Administration has recommended continuation without modification of an ongoing Phase 3 PRESECO (PREventing SEvere COvid-19) trial that is evaluating Avigan as a potential outpatient oral therapy for patients with mild-to-moderate Covid-19. Interim results indicate that Avigan, the brand name for generic Favipiravir, could shorten recovery times and prevent progression in Covid-19 patients in the early stage of infection. The conclusion of the midterm analysis is that, if current trends continue, the required statisticall

United arab emiratesMitch wilsonRichard kaszynskiAvigan reeqonusDrug administrationTradearabia news serviceGlobal response aidSafety monitoring boardAppili therapeuticsFujifilm toyama chemicalArabia newsRade arabiaIddle east trade newsCc business newsNdustry newsTrade news

DIP rejects bid to patent Covid treatment

DIP rejects bid to patent Covid treatment 2 published : 6 May 2021 at 04:44 Vuttikrai: Free for all to produce The Department of Intellectual Property (DIP) has rejected a request to patent the anti-viral drug Favipiravir which is being administered to patients with few if any Covid-19 symptoms. Vuttikrai Leewiraphan, the department director-general, ruled that the request by a manufacturer to patent the drug in its tablet form did not constitute an advanced invention under the 1979 Patent Act. The applicant was allowed to submit additional paperwork but still fell short of qualifying for the patent, he said. Mr Vuttikrai said nobody could claim exclusive rights to produce or sell Favipiravir in Thailand and both the Government Pharmaceutical Organisation and any private company in Thailand were free to produce it.

Krung thep mahanakhonVuttikrai leewiraphanPol gen aswinPublic health ministryGovernment pharmaceutical organisationDepartment of intellectual propertyIntellectual propertyFujifilm toyama chemicalபோல் கேன் அஸ்வின்பொது ஆரோக்கியம் அமைச்சகம்அரசு மருந்து ஆர்கநைஸேஶந்துறை ஆஃப் அறிவுசார் ப்ராபர்டீஅறிவுசார் ப்ராபர்டீபுஜிஃபில்ம் டோயாமா இரசாயன